|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/15/20 Cell MedX Corp. 10-K 5/31/20 84:2.9M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 495K
2: EX-10.68 Loan Agreement and Note Payable Dated April 13, HTML 28K
2020, Among Cell Medx Corp. and Longview
Investment Limited
3: EX-10.69 Loan Agreement Dated July 3, 2020, Among Cell Medx HTML 30K
Corp. and David Jeffs
4: EX-10.70 Loan Agreement and Note Payable Dated August 31, HTML 28K
2020, Among Cell Medx Corp. and Tradex Capital
Corp.
5: EX-21.1 List of Subsidiaries HTML 23K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
16: R1 Document and Entity Information HTML 79K
17: R2 Consolidated Balance Sheets HTML 92K
18: R3 Consolidated Balance Sheets - Parenthetical HTML 30K
19: R4 Consolidated Statements of Operations HTML 86K
20: R5 Consolidated Statement of Stockholders' Deficit HTML 71K
21: R6 Consolidated Statements of Cash Flows HTML 97K
22: R7 Organization and Nature of Operations HTML 28K
23: R8 Summary of Significant Accounting Policies HTML 39K
24: R9 Related Party Transactions Disclosure HTML 38K
25: R10 Inventory Disclosure HTML 27K
26: R11 Other Current Assets Disclosure HTML 26K
27: R12 Equipment Disclosure HTML 31K
28: R13 Unearned Revenue Disclosure HTML 40K
29: R14 Revenue Disclosure HTML 29K
30: R15 Notes and Advances Payable Disclosure HTML 46K
31: R16 Share Capital Disclosure HTML 46K
32: R17 Income Taxes Disclosure HTML 39K
33: R18 Subsequent Event Disclosure HTML 27K
34: R19 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis HTML 26K
of Presentation (Policies)
35: R20 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Principles of Consolidation, Policy (Policies)
36: R21 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 29K
Accounting Estimates, Policy (Policies)
37: R22 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Foreign Currency Translations and Transactions,
Policy (Policies)
38: R23 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Revenue Recognition, Policy (Policies)
39: R24 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Inventory Valuation, Policy (Policies)
40: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Research and Development Costs, Policy (Policies)
41: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income HTML 30K
Taxes, Policy (Policies)
42: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Loss HTML 27K
Per Share, Policy (Policies)
43: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Long-lived Assets, Policy (Policies)
44: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Equipment, Policy (Policies)
45: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair HTML 28K
Value Measurements, Policy (Policies)
46: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock HTML 28K
Options and Other Stock-based Compensation, Policy
(Policies)
47: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent HTML 27K
Accounting Pronouncements (Policies)
48: R33 Related Party Transactions Disclosure: Schedule of HTML 31K
Amounts Due to Related Parties (Tables)
49: R34 Related Party Transactions Disclosure: Schedule of HTML 30K
Transactions with Related Parties (Tables)
50: R35 Equipment Disclosure: Change in book value of the HTML 30K
equipment (Tables)
51: R36 Unearned Revenue Disclosure: Changes to Unearned HTML 32K
Revenue (Tables)
52: R37 Unearned Revenue Disclosure: Schedule of Loss on HTML 28K
Reacquisition of Distribution Rights (Tables)
53: R38 Revenue Disclosure: Schedule of Revenue and HTML 28K
Associated Costs (Tables)
54: R39 Notes and Advances Payable Disclosure: Schedule of HTML 38K
Short-term Loans and Advances Outstanding (Tables)
55: R40 Share Capital Disclosure: Schedule of Stock Option HTML 31K
Activity (Tables)
56: R41 Share Capital Disclosure: Schedule of Stock HTML 29K
Options Outstanding (Tables)
57: R42 Share Capital Disclosure: Schedule of Warrant HTML 28K
Activity (Tables)
58: R43 Share Capital Disclosure: Schedule of Warrant HTML 31K
Details (Tables)
59: R44 Income Taxes Disclosure: Schedule of Effective HTML 32K
Income Tax Rate Reconciliation (Tables)
60: R45 Income Taxes Disclosure: Schedule of Deferred Tax HTML 30K
Assets and Liabilities (Tables)
61: R46 Organization and Nature of Operations (Details) HTML 27K
62: R47 Related Party Transactions Disclosure: Schedule of HTML 36K
Amounts Due to Related Parties (Details)
63: R48 Related Party Transactions Disclosure: Schedule of HTML 34K
Transactions with Related Parties (Details)
64: R49 Inventory Disclosure (Details) HTML 36K
65: R50 Other Current Assets Disclosure (Details) HTML 28K
66: R51 Equipment Disclosure: Change in book value of the HTML 33K
equipment (Details)
67: R52 Unearned Revenue Disclosure: Changes to Unearned HTML 38K
Revenue (Details)
68: R53 Unearned Revenue Disclosure (Details) HTML 37K
69: R54 Unearned Revenue Disclosure: Schedule of Loss on HTML 31K
Reacquisition of Distribution Rights (Details)
70: R55 Revenue Disclosure: Schedule of Revenue and HTML 41K
Associated Costs (Details)
71: R56 Notes and Advances Payable Disclosure: Schedule of HTML 46K
Short-term Loans and Advances Outstanding
(Details)
72: R57 Notes and Advances Payable Disclosure (Details) HTML 41K
73: R58 Share Capital Disclosure (Details) HTML 61K
74: R59 Share Capital Disclosure: Schedule of Stock Option HTML 32K
Activity (Details)
75: R60 Share Capital Disclosure: Schedule of Stock HTML 34K
Options Outstanding (Details)
76: R61 Share Capital Disclosure: Schedule of Warrant HTML 30K
Activity (Details)
77: R62 Share Capital Disclosure: Schedule of Warrant HTML 41K
Details (Details)
78: R63 Income Taxes Disclosure: Schedule of Effective HTML 45K
Income Tax Rate Reconciliation (Details)
79: R64 Income Taxes Disclosure: Schedule of Deferred Tax HTML 32K
Assets and Liabilities (Details)
80: R65 Income Taxes Disclosure (Details) HTML 28K
81: R66 Subsequent Event Disclosure (Details) HTML 32K
83: XML IDEA XML File -- Filing Summary XML 151K
82: EXCEL IDEA Workbook of Financial Reports XLSX 75K
10: EX-101.INS XBRL Instance -- cmxc-20200531 XML 637K
12: EX-101.CAL XBRL Calculations -- cmxc-20200531_cal XML 74K
13: EX-101.DEF XBRL Definitions -- cmxc-20200531_def XML 309K
14: EX-101.LAB XBRL Labels -- cmxc-20200531_lab XML 543K
15: EX-101.PRE XBRL Presentations -- cmxc-20200531_pre XML 505K
11: EX-101.SCH XBRL Schema -- cmxc-20200531 XSD 149K
84: ZIP XBRL Zipped Folder -- 0001393905-20-000276-xbrl Zip 69K
| ex-10.70 |
LOAN AGREEMENT
Tradex Capital Corp., (the “Lender”) with an address at 1177 W. Hastings Street, Suite 2288, Vancouver, BC V6E 2K3, advanced USD$65,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on August 31, 2020.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from August 31, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
| LENDER | BORROWER |
| Tradex Capital Corp. | Cell MedX Corp. |
|
|
|
| Per: | Per: |
|
|
|
|
|
|
| /s/ William Friesen | /s/ Yanika Silina |
| Name: Rick Donaldson | Yanika Silina, CFO |
PROMISSORY NOTE
| Principal Amount: USD$65,000 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Tradex Capital Corp., (the “Lender”) the sum of $65,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from August 31, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/15/20 | |||
| 8/31/20 | 10-Q, NT 10-K | |||
| For Period end: | 5/31/20 | NT 10-K | ||
| List all Filings | ||||